摘要
目的探讨西妥昔单抗联合同期顺铂化疗加调强放疗治疗局部晚期鼻咽癌的临床疗效及安全性。方法选择2009年1月至2012年1月我院收治的晚期鼻咽癌患者110例为研究对象,随机分为对照组和观察组,每组55例,对照组患者给予单纯调强适形放射治疗,而观察组患者给予西妥昔单抗联合同期顺铂化疗加调强放疗,治疗4个周期后比较两组患者的临床疗效及其不良反应的发生情况。结果对照组和观察组的治疗总有效率分别为74.5%和92.7%,观察组明显高于对照组(P<0.05)。两组患者治疗过程中均出现不同程度的恶心、呕吐等消化道反应及骨髓抑制,经对症处理后,明显好转;观察组患者皮肤痤疮样皮疹及口腔黏膜炎的发生率明显高于对照组(P<0.05)。结论西妥昔单抗联合同期顺铂化疗加调强放疗治疗局部晚期鼻咽癌的近期疗效好,但不良反应多,临床需综合考虑后推广应用。。
Objective To investigate the efficacy and safety of cetuximab combined with cisplatin chemotherapy and intensity-modulated radiotherapy in the treatment of locally advanced nasopharyngeal carcinoma. Methods 110 cases of locally advanced nasopharyngeal carcinoma hospitalized from January 2009 to January 2012 were selected and randomly divided into the control group and observation group (55 cases in each group). The control group was treated by intensity-modulated radiotherapy, while the observation group was treated by cetuximab combined with cisplatin chemotherapy and intensitymodulated radiotherapy. The clinical efficacy and incidence rates were compared between two groups after 4 treatment cycles. Results The total effective rates of control group and observation group were respectively 74.5% and 92.7%, which was significantly higher in the observation group (P〈0.05). Gastrointestinal reactions such as nausea and vomitting as well as myelosuppression were observed in two groups, but were obviously improved after symptomatic treatment. The incidence rates of ache-like rash and oral mucositis were significantly higher in the observation group than those of the control group (P〈0.1)5). Conclusion Cetuximab plus cisplatin chemotherapy and intensity-modulated radiotherapy had better clinical efficacy but more adverse reactions in the treatment of locally advanced nasopharyngeal carcinoma. It should be applied in clinic after overall consideration.
出处
《肿瘤药学》
CAS
2013年第2期119-121,129,共4页
Anti-Tumor Pharmacy
关键词
西妥昔单抗
顺铂
调强放疗
鼻咽癌
临床疗效
Cetuximab
Cisptatin
Intensity-modulated radiotherapy
Nasopharyngeal carcinoma
Clinical efficacy